SIPPET: insights into factor VIII immunogenicity-Reference-Cited by-同舟云学术

SIPPET: insights into factor VIII immunogenicity

Published:2017-11-18 Issue:1 Volume:16 Page:36-38
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Fallon P. G.¹,Lavin M.²³,O'Donnell J. S.²³

Affiliation:

1. School of Medicine; Trinity Translational Medicine Institute; St James's Hospital; Trinity College Dublin; Dublin Ireland

2. Irish Centre for Vascular Biology; Royal College of Surgeons in Ireland; Dublin Ireland

3. National Coagulation Centre; St James's Hospital; Dublin Ireland

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13886/fullpdf

Reference14 articles.

1. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis;Peyvandi;J Thromb Haemost,2017

2. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom;Hay;Blood,2011

3. Inhibitors - genetic and environmental factors;Lillicrap;Haemophilia,2014

4. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A;Peyvandi;N Engl J Med,2016

5. Plasma products do not solve the inhibitor problem;Berg;Haemophilia,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs for hemophilia A: insights into phase II and III clinical trials;Expert Opinion on Emerging Drugs;2021-10-02

2. Consenso de hemofilia en México;Gaceta de M�xico;2021-04-09

3. The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A;Transfusion and Apheresis Science;2018-08